New England Journal of Medicine July 2, 2015

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.

Bottom Line

In previously untreated advanced melanoma, combining the immune checkpoint inhibitors nivolumab and ipilimumab, or using nivolumab alone, significantly improved progression-free survival compared to single-agent ipilimumab.

Key Findings

1. Medianprogression-freesurvival(PFS)wassignificantlylongerwithnivolumabplusipilimumab(11.5months)andnivolumabalone(6.9months)comparedtoipilimumabalone(2.9months)[1.4].

2. The combination of nivolumab plus ipilimumab reduced the risk of death or disease progression by 58% compared to ipilimumab alone (HR 0.42; 99.5% CI, 0.31-0.57; P<0.001).

3. Nivolumab monotherapy reduced the risk of disease progression by 43% compared to ipilimumab alone (HR 0.57; 99.5% CI, 0.43-0.76; P<0.001).

4. Objective response rates (ORR) were highest in the combination group (57.6%), compared to 43.7% in the nivolumab group and 19.0% in the ipilimumab group.

5. In patients with PD-L1-negative tumors, combination therapy demonstrated a numerical PFS advantage over nivolumab alone (11.2 months vs. 5.3 months), whereas in PD-L1-positive tumors, median PFS was identical (14.0 months) for both groups.

6. Grade 3 or 4 treatment-related adverse events were significantly higher with the combination (55.0%) compared to nivolumab (16.3%) or ipilimumab (27.3%) alone.

Study Design

Design

Phase 3 RCT

Double-Blind

Sample

945

Patients

Duration

9 mo

Median

Setting

Multinational

Population Patients with previously untreated, unresectable stage III or stage IV advanced melanoma.

Intervention Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for 4 doses, followed by nivolumab 3 mg/kg every 2 weeks; OR Nivolumab 3 mg/kg every 2 weeks plus placebo

Comparator Ipilimumab 3 mg/kg every 3 weeks for 4 doses plus placebo

Outcome Progression-free survival (PFS) and overall survival (OS) (coprimary endpoints)

Study Limitations

• Overall survival (OS), a coprimary endpoint, was immature at the time of the initial 2015 report (though later follow-ups demonstrated a sustained OS benefit).

• The study was not formally powered for a direct statistical comparison of the primary endpoints between the nivolumab-plus-ipilimumab combination group and the nivolumab monotherapy group.

• The combination regimen was associated with a substantially higher incidence of high-grade toxicities, resulting in more frequent treatment discontinuations.

• The study highlighted the need for definitive predictive biomarkers (beyond PD-L1 expression) to clearly identify which patients absolutely require the more toxic combination therapy rather than anti-PD-1 monotherapy.

Clinical Significance

CheckMate 067 was a practice-changing trial that established the combination of CTLA-4 blockade (ipilimumab) and PD-1 blockade (nivolumab) as a highly efficacious frontline standard of care for patients with advanced melanoma. By proving that dual immune checkpoint blockade yields vastly superior response rates and progression-free survival compared to single-agent ipilimumab, the trial revolutionized the immunotherapeutic treatment paradigm. It validated the biological concept that synergistically targeting distinct immunological pathways can overcome single-agent resistance, albeit at the cost of higher immune-mediated toxicity.

Historical Context

Prior to 2011, metastatic melanoma was notoriously refractory to systemic therapy, with a median survival of merely 6 to 9 months and dismal long-term outcomes. The approval of ipilimumab (an anti-CTLA-4 antibody) in 2011 was a watershed moment, showing for the first time that immune checkpoint blockade could improve overall survival in this disease. Subsequently, anti-PD-1 agents like nivolumab and pembrolizumab demonstrated even higher efficacy and better safety profiles than ipilimumab. CheckMate 067 was designed following promising phase 1/2 data to definitively test whether simultaneous blockade of both the CTLA-4 and PD-1 pathways could provide complementary activation of T-cells, thereby elevating the ceiling of immunotherapeutic efficacy in untreated advanced melanoma.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What are the distinct mechanisms of action of nivolumab and ipilimumab, and why does combining these two immune checkpoint inhibitors theoretically provide a synergistic effect against melanoma?

Key Response

Ipilimumab blocks CTLA-4, which primarily acts during the priming phase of T-cell activation in the lymph nodes. Nivolumab blocks PD-1, which operates during the effector phase within the tumor microenvironment to prevent T-cell exhaustion. Combining them targets two distinct, non-redundant immune evasion pathways, leading to synergistic anti-tumor activity.

Resident

Given the significant efficacy benefits of the nivolumab plus ipilimumab combination, how do the rates and management of Grade 3 or 4 immune-related adverse events differ between the combination therapy and nivolumab monotherapy?

Key Response

The combination regimen has a much higher rate of Grade 3 or 4 adverse events (over 50%) compared to nivolumab alone (around 16%). Residents must be hyper-vigilant for toxicities like colitis, pneumonitis, and endocrinopathies, which require prompt recognition, holding of immunotherapy, and rapid initiation of high-dose corticosteroids or secondary immunosuppressants like infliximab.

Fellow

CheckMate-067 suggested that PD-L1 expression levels might identify patients who benefit from monotherapy versus combination therapy. How should a medical oncology fellow integrate PD-L1 expression status into shared decision-making for untreated advanced melanoma?

Key Response

Exploratory analyses suggested patients with PD-L1 >= 5% might have similar progression-free survival with nivolumab alone versus the combination, though the trial was not powered to formally test equivalence. Fellows must weigh numerical survival trends against the severe toxicity of combination therapy, recognizing PD-L1 is an imperfect biomarker in melanoma compared to its utility in non-small cell lung cancer.

Attending

As long-term survival data from CheckMate-067 continue to mature, how does the concept of a functional cure or plateauing survival curve alter our goals of care discussions and survivorship care plans for metastatic melanoma patients?

Key Response

The plateauing of the survival curve at around 50% for the combination arm fundamentally shifted metastatic melanoma from an almost universally fatal disease to a chronic or potentially curable one. Attendings must balance hope for durable remission with the proactive management of irreversible, lifelong toxicities, such as permanent hypopituitarism or type 1 diabetes, in long-term survivorship clinics.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The CheckMate-067 trial was powered to compare the combination to ipilimumab and nivolumab to ipilimumab, but was not explicitly powered to compare the combination directly against nivolumab monotherapy. How does this hierarchical testing design impact the interpretation of the incremental benefit of the combination, and what statistical methods could address this limitation?

Key Response

Because the trial lacked formal prespecified statistical power for the combination versus nivolumab comparison, claims of clinical superiority rely on descriptive statistics and post-hoc hazard ratios rather than formal hypothesis testing. This highlights the importance of rigorous alpha allocation in trial design and how structural choices affect clinical dogma.

Journal Editor

In reviewing the manuscript, how does the absence of a protocolized cross-over design for patients progressing on monotherapy influence the interpretation of overall survival outcomes, and what confounding factors might a reviewer flag regarding subsequent lines of therapy?

Key Response

Patients progressing on ipilimumab alone could potentially receive anti-PD-1 therapy off-protocol in subsequent lines, which confounds overall survival outcomes. A critical reviewer would heavily scrutinize the supplementary data on subsequent therapies to determine if the survival benefit of upfront combination therapy is genuinely superior to the sequential administration of these targeted agents.

Guideline Committee

Based on CheckMate-067, both NCCN and ESMO guidelines recommend the combination and anti-PD-1 monotherapy as high-level evidence options. What specific clinical criteria should guidelines emphasize to help clinicians choose between combination therapy and monotherapy as first-line treatment?

Key Response

Guidelines must synthesize efficacy versus toxicity. They recommend the combination for patients who can tolerate significant toxicity, particularly those with asymptomatic brain metastases, elevated LDH, or BRAF mutations, while reserving monotherapy for frail patients or those where avoiding toxicity is paramount. The committee must grade this evidence as Level I while providing nuanced, patient-specific clinical pathways.

Clinical Landscape

Noteworthy Related Trials

2015

KEYNOTE-006 Trial

n = 834 · NEJM

Tested

Pembrolizumab 10 mg/kg every 2 or 3 weeks

Population

Patients with advanced melanoma

Comparator

Ipilimumab 3 mg/kg

Endpoint

Progression-free survival and overall survival

Key result: Pembrolizumab significantly prolonged progression-free and overall survival compared to ipilimumab, with less high-grade toxicity.

2015

CheckMate-066 Trial

n = 418 · NEJM

Tested

Nivolumab 3 mg/kg every 2 weeks

Population

Previously untreated BRAF wild-type advanced melanoma

Comparator

Dacarbazine

Endpoint

Overall survival

Key result: Nivolumab significantly improved overall survival compared to dacarbazine.

2022

RELATIVITY-047 Trial

n = 714 · NEJM

Tested

Relatlimab and nivolumab fixed-dose combination

Population

Previously untreated advanced melanoma

Comparator

Nivolumab monotherapy

Endpoint

Progression-free survival

Key result: The combination of relatlimab and nivolumab significantly prolonged progression-free survival compared to nivolumab alone.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis